First-of-its-Kind gene therapy injected into spine to fight Alzheimer's
NCT ID NCT03634007
Summary
This early-stage study tested the safety of a new gene therapy, called LX1001, for Alzheimer's disease. It involved 15 people with early to moderate Alzheimer's who all carry two copies of a specific genetic risk factor (APOE4). The therapy was delivered via a single injection into the spinal fluid, aiming to change a protein in the brain linked to the disease.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Duke University
Durham, North Carolina, 27708, United States
-
K2 Medical Research
Maitland, Florida, 32751, United States
-
PPD- Orlando Research Unit
Orlando, Florida, 32806, United States
-
Weill Cornell Medicine
New York, New York, 10021, United States
Conditions
Explore the condition pages connected to this study.